BRII-196

BIOLOGICAL2 trials

Sponsors

Brii Biosciences Limited, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19

Phase 1

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

CompletedNCT04479631

Brii Biosciences LimitedCOVID-19

Start: 2020-07-12End: 2021-01-29Updated: 2023-03-03

Phase 3

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

CompletedNCT05780424

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2020-12-16End: 2022-10-10Updated: 2024-02-05

Related Papers

Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults

Frontiers in Pharmacology2022-09-0611 citations